Journal article

mTOR Signalling in Head and Neck Cancer: Heads Up

Fiona H Tan, Yuchen Bai, Pierre Saintigny, Charbel Darido

CELLS | MDPI | Published : 2019

Abstract

The mammalian target of rapamycin (mTOR) signalling pathway is a central regulator of metabolism in all cells. It senses intracellular and extracellular signals and nutrient levels, and coordinates the metabolic requirements for cell growth, survival, and proliferation. Genetic alterations that deregulate mTOR signalling lead to metabolic reprogramming, resulting in the development of several cancers including those of the head and neck. Gain-of-function mutations in EGFR, PIK3CA, and HRAS, or loss-of-function in p53 and PTEN are often associated with mTOR hyperactivation, whereas mutations identified from The Cancer Genome Atlas (TCGA) dataset that potentially lead to aberrant mTOR signalli..

View full abstract

Grants

Awarded by Australian National Health and Medical Research (NHMRC)


Awarded by Association for International Cancer Research (AICR)


Awarded by Victorian Cancer Agency


Awarded by French LYriCAN grant


Funding Acknowledgements

This research was funded by the Australian National Health and Medical Research (NHMRC, grant numbers APP1049870, APP1106697) and The Association for International Cancer Research (AICR, 11-0060). The authors were funded by Fellowships from the Victorian Cancer Agency (Clare Oliver Memorial, COF11_04 and Mid-Career, MCRF16017) to C.D. and by the French LYriCAN grant (INCa-DGOS-Inserm_12563) to P.S.